Disease · MONDO_0005984

tinea pedis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. tinea pedis. Diseases, record MONDO_0005984. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005984

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: tinea pedis; Open Targets
Open Targets ID: MONDO_0005984; Open Targets
Other names: Dermatophytosis of foot (& tinea pedis), Dermatophytosis of foot (disorder), Tinea pedis (disorder), athlete's foot, dermatophytosis of foot, dermatophytosis of pes, pes dermatophytosis; Open Targets
Disease Ontology: DOID:12403; Disease Ontology
MeSH: D014008; MeSH
Highest stage of its drugs: Approval, for 15 of its 34 drugs, from DailyMed and TTD; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NAFTIFINE HYDROCHLORIDE	CHEMBL1200493	Small molecule	Approval	DailyMed	16	7	7	Drugs and targets
ECONAZOLE NITRATE	CHEMBL1201049	Small molecule	Approval	DailyMed	7	5	5	Drugs and targets
LULICONAZOLE	CHEMBL2105689	Small molecule	Approval	DailyMed and TTD	6	4	4	Drugs and targets
KETOCONAZOLE	CHEMBL157101	Small molecule	Approval	DailyMed	5	4	4	Drugs and targets
CLOTRIMAZOLE	CHEMBL104	Small molecule	Approval	DailyMed	7	2	2	Drugs and targets
CICLOPIROX	CHEMBL1413	Small molecule	Approval	DailyMed	5	2	2	Drugs and targets
TOLNAFTATE	CHEMBL83668	Small molecule	Approval	DailyMed	5	2	2	Drugs and targets
OXICONAZOLE NITRATE	CHEMBL1200836	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
SERTACONAZOLE NITRATE	CHEMBL1200725	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
GRISEOFULVIN	CHEMBL562	Small molecule	Approval	DailyMed	4	1	1	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
GUCY1A1	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 2	https://conductscience.org/library/genes/2982	Drugs and targets
GUCY1A2	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 2	https://conductscience.org/library/genes/2977	Drugs and targets
GUCY1B1	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 2	https://conductscience.org/library/genes/2983	Drugs and targets

Trials56

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03129321	Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis	Phase 3	876	2018-08-02	Tinea Pedis	ECONAZOLE NITRATE	Its record names the disease	ClinicalTrials.gov
NCT01290341	Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis	Phase 3	860	2013-09-26	Tinea Pedis	NAFTIFINE	Its record names the disease	ClinicalTrials.gov
NCT01289015	Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis	Phase 3	855	2013-09-26	Tinea Pedis	NAFTIFINE	Its record names the disease	ClinicalTrials.gov
NCT03824912	Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis	Phase 3	831	2019-06-13	Tinea Pedis	KETOCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00750139	Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis	Phase 3	707	2013-01-29	Tinea Pedis, Athlete's Foot	NAFTIFINE	Its record names the disease	ClinicalTrials.gov
NCT01110330	An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot	Phase 3	583	2013-06-06	Tinea Pedis	KETOCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00802672	Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis	Phase 3	561	2012-06-19	Tinea Pedis	CICLOPIROX, CICLOPIROX OLAMINE	Its record names the disease	ClinicalTrials.gov
NCT00804193	Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis	Not applicable	553	2012-12-17	Tinea Pedis	CICLOPIROX, CICLOPIROX OLAMINE	Its record names the disease	ClinicalTrials.gov
NCT00835510	Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis	Phase 1	548	2009-10-06	Tinea Pedis	BUTENAFINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00750152	Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris	Phase 3	334	2012-03-13	Tinea Cruris, Jock Itch	NAFTIFINE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 56

See all 56 trials

Comparisons in its trials21

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
NAFT-600 vs Placebo: serious adverse events	1 of 572	2 of 287	859	NCT01290341	Trial comparisons
NAFT-600 vs Placebo: serious adverse events	2 of 571	2 of 284	855	NCT01289015	Trial comparisons
Test: Ketoconazole Cream 2% vs Reference: Ketoconazole Cream 2%: Secondary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Clinical Cure of Tinea Pedis (Equivalence: Per-Protocol Population)	97 of 184	110 of 191	375	NCT03824912	Trial comparisons
Test: Ketoconazole Cream 2% vs Reference: Ketoconazole Cream 2%: Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population)	89 of 184	90 of 191	375	NCT03824912	Trial comparisons
Test: Ketoconazole Cream 2% vs Reference: Ketoconazole Cream 2%: Secondary Efficacy Endpoint:The Number of Patients in Each Treatment Group With a Mycological Cure of Tinea Pedis (Equivalence: Per-Protocol Population)	127 of 184	118 of 190	374	NCT03824912	Trial comparisons
Test vs Reference Standard: Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure	96 of 185	81 of 170	355	NCT03129321	Trial comparisons
Test vs Reference Standard: Proportion of Patients in Each Active Treatment Group Who Are Considered a Mycological Cure	136 of 185	125 of 170	355	NCT03129321	Trial comparisons
Test vs Reference Standard: Proportion of Patients in Each Active Treatment Group Who Are Considered a Clinical Cure (Patient's Total Severity Score Must be ≤ 2 With no Individual Severity Score > 1)	113 of 185	99 of 170	355	NCT03129321	Trial comparisons
NAFT-500 vs Placebo-2wks: serious adverse events	0 of 166	0 of 168	334	NCT00750152	Trial comparisons
Terbinafine vs Placebo: Number of Subjects With Adverse Event	9 of 146	11 of 144	290	NCT01433107	Trial comparisons

1 to 10 of 21

See all 21 comparisons in its trials

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26276254	RESULT	1	PubMed
21968664	RESULT	1	PubMed
22052309	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005984

GET https://conductscience.org/api/diseases/v1/MONDO_0005984/drugs?page=2

API reference For AI assistants